Form 4: Sutro Biopharma Grants Options to Chief Admin Officer

Sutro Biopharma's Chief Administrative Officer and General Counsel, David Pauling, was granted 7,200 stock options with an exercise price of $10.38, vesting monthly over four years.

Summary

• David Pauling, Chief Administrative Officer and General Counsel of Sutro Biopharma, Inc. (STRO), was granted 7,200 stock options.
• The options have an exercise price of $10.38 per share.
• The grant date for these options was December 23, 2025.
• The options vest monthly over a four-year period, with 1/48th of the total award vesting each month.
• The first tranche of options is scheduled to vest on January 23, 2026.
• The options expire on December 23, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• A Limited Power of Attorney was granted by David Pauling to Regina Cheng and Gregory Chow on October 7, 2025, to execute and file Section 16 forms (Forms 3, 4, and 5) on his behalf.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of executive compensation, which is generally positive for aligning management incentives. No significant negative news, but also no major positive operational or financial news.

Positives

• Granting of stock options aligns management incentives with shareholder interests.
• The Rule 10b5-1 plan indicates a structured approach to future potential transactions, reducing insider trading concerns.

Negatives

• The options do not represent an immediate cash benefit to the officer.
• Potential for future dilution if options are exercised and new shares are issued.

Risks

• The value of the options is subject to the future market price of Sutro Biopharma's common stock.
• Vesting is contingent on David Pauling's continued service to the company.
• If the stock price does not exceed the exercise price of $10.38, the options may expire worthless.

Future Outlook

The stock options granted to David Pauling are structured to vest monthly over a four-year period, with the first vesting event scheduled for January 23, 2026, aligning his long-term incentives with the company's future performance.

Industry Context

The granting of stock options to key executives like the Chief Administrative Officer is a standard practice in the biopharmaceutical industry, aiming to attract, retain, and motivate talent by aligning their financial interests with the long-term success and stock performance of the company. This is particularly common in growth-oriented sectors like biotech where long development cycles necessitate long-term incentive structures.

Comparison to Industry Standards

• The four-year monthly vesting schedule is a common industry standard for executive equity awards, similar to practices at companies like Moderna or BioNTech for their senior leadership.
• The use of a Rule 10b5-1 plan for insider transactions is a best practice widely adopted across public companies to demonstrate compliance with insider trading regulations and provide transparency.
• The exercise price being at or above the market price on the grant date (implied, as it's an option grant) is typical for incentive stock options, ensuring the executive benefits only if the stock appreciates.

Corporate Governance

Related Party Transactions

• Grant of 7,200 stock options to David Pauling, Chief Administrative Officer and General Counsel, as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefits from aligning executive incentives with long-term stock performance.
• Employees: Standard executive compensation practices can signal stability and competitive compensation structures within the company.
• Management: David Pauling receives a long-term incentive, tying his financial success to the company's stock performance.

Next Steps

• Monthly vesting of 1/48th of the options will occur, starting January 23, 2026, contingent on David Pauling's continued service.
• David Pauling may exercise vested options at any time before the expiration date of December 23, 2035.

Key Dates

Recommendation

This Form 4 filing is a routine disclosure of executive compensation and does not contain information that would fundamentally alter the investment thesis for Sutro Biopharma. The grant of stock options aligns management incentives with shareholder interests, which is a positive, but it's not a catalyst for a 'buy' or 'sell' recommendation. Investors should continue to hold based on the company's underlying fundamentals and broader market conditions.

Keywords

Sutro Biopharma, STRO, Stock Options, Form 4, Insider Trading, Executive Compensation, David Pauling, Rule 10b5-1, Biopharma